Summary
Quest Diagnostics reported mixed financial results for the nine months and third quarter ended September 30, 2016. While overall net revenues saw a slight increase of 0.2% year-over-year for the nine-month period, driven by a 2.7% rise in its core Diagnostic Information Services (DIS) segment, the company's Diagnostic Solutions (DS) segment experienced a significant 30.7% revenue decline due to divestitures. Net income attributable to Quest Diagnostics stockholders decreased by 6.1% for the nine months, impacted by various one-time items including a gain from the sale of the Focus Diagnostics business and charges related to debt retirement and restructuring. However, cash flow from operations remained strong, increasing by $216 million for the nine-month period, indicating solid underlying operational performance. The company continued its strategic divestitures, notably the sale of its Focus Diagnostics products business, which generated a substantial pre-tax gain. This aligns with management's strategy to refocus on its core diagnostic information services. Quest Diagnostics also actively managed its capital structure, repurchasing shares and completing debt refinancing activities. Despite a decrease in net income, the company's operational cash generation and strategic divestitures suggest a continued focus on efficiency and core business strength.
Financial Highlights
57 data points| Revenue | $1.89B |
| Cost of Revenue | $1.16B |
| Gross Profit | $728.00M |
| SG&A Expenses | $409.00M |
| Operating Expenses | $1.56B |
| Operating Income | $322.00M |
| Interest Expense | $37.00M |
| Net Income | $192.00M |
| EPS (Basic) | $1.37 |
| EPS (Diluted) | $1.34 |
| Shares Outstanding (Basic) | 139.00M |
| Shares Outstanding (Diluted) | 142.00M |
Key Highlights
- 1Net revenues for the nine months ended September 30, 2016, increased slightly by 0.2% to $5.65 billion, while the third quarter saw a 0.3% increase to $1.89 billion.
- 2The Diagnostic Information Services (DIS) segment, representing over 90% of revenue, showed growth with a 2.7% increase for the nine months and a 2.1% increase for the third quarter.
- 3Diagnostic Solutions (DS) segment revenues declined significantly by 30.7% for the nine months and 27.1% for the third quarter, largely due to the divestiture of the Focus Diagnostics business.
- 4Net income attributable to Quest Diagnostics stockholders decreased by 6.1% to $490 million for the nine months and by 44.0% to $192 million for the third quarter, impacted by significant one-time items including a gain on sale of business and debt retirement costs.
- 5Cash flow from operating activities for the nine months increased by $216 million to $765 million, demonstrating strong operational cash generation.
- 6The company completed the sale of its Focus Diagnostics products business for $293 million net, recognizing a pre-tax gain of $118 million for the nine months.
- 7Quest Diagnostics actively repurchased shares, spending $440 million in the nine months ended September 30, 2016, including an accelerated share repurchase agreement.